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Thrombosis and its complications are the leading cause of death in patients with diabetes. Metformin, 
a first-line therapy for type 2 diabetes, is the only drug demonstrated to reduce cardiovascular 
complications in diabetic patients. However, whether metformin can effectively prevent thrombosis 
and its potential mechanism of action is unknown. Here we show, metformin prevents both venous 
and arterial thrombosis with no significant prolonged bleeding time by inhibiting platelet activation 
and extracellular mitochondrial DNA (mtDNA) release. Specifically, metformin inhibits mitochondrial 
complex I and thereby protects mitochondrial function, reduces activated platelet-induced 
mitochondrial hyperpolarization, reactive oxygen species overload and associated membrane damage. 
In mitochondrial function assays designed to detect amounts of extracellular mtDNA, we found that 
metformin prevents mtDNA release. This study also demonstrated that mtDNA induces platelet 
activation through a DC-SIGN dependent pathway. Metformin exemplifies a promising new class of 
antiplatelet agents that are highly effective at inhibiting platelet activation by decreasing the release 
of free mtDNA, which induces platelet activation in a DC-SIGN-dependent manner. This study has 
established a novel therapeutic strategy and molecular target for thrombotic diseases, especially for 
thrombotic complications of diabetes mellitus.
Worldwide, 415 million people, or 1 in 11 adults, are estimated to have diabetes mellitus (DM). Approximately 
5.0 million people died from DM in 2015, which is equivalent to one death every six seconds1–3. Thrombosis is the 
leading cause of morbidity and mortality in patients with DM, with a reported 65% of diabetic patients eventually 
dying from thrombotic diseases4–6. However, an increased understanding of the mechanisms of thrombogenesis 
has led to a new era in the discovery of antithrombotic agents that target many of the key steps in blood coagula-
tion and platelet activation7. Metformin is widely used as the first-line therapy for type-2 diabetic patients. It has 
been reported that metformin reduced mortality and diabetes-associated thrombotic complications8–12. However, 
its mechanism of action is largely unknown with respect to thrombosis prevention, and further investigation is 
merited.
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In 2000, two independent publications showed that metformin protects mitochondrial function by inhibiting 
complex I in the mitochondrial respiratory chain13,14. In 2010, it was reported that metformin use may decrease 
mortality among patients with diabetes and atherothrombosis9. Numerous studies have reported that mitochon-
drial function is associated with platelet activation and thrombosis15–18. For example, Brownlee and colleagues 
demonstrated that hyperglycaemia induces mitochondrial hyperpolarization in normal platelets, resulting in the 
augmentation of reactive oxygen species (ROS) generation and subsequent activation16. Cardenes et al. found 
that mitochondrial alterations cause platelet activation in vitro and in vivo17, while Boudreau et al. reported that 
activated platelets can release mitochondria18. However, it is not known whether metformin is associated with 
platelet activation. We hypothesized that metformin can inhibit platelet activation and platelet-activated blood 
coagulation by preventing platelet mitochondrial dysfunction and release.
Results
Metformin suppresses mtDNA release and mitochondrial dysfunction of activated platelets. 
We first determined the amounts of extracellular mtDNA detected from ADP-activated platelets in vitro (Fig. 1A, 
metformin: 1 mM, 6 h, 37 °C) and in vivo (Fig. 1B, metformin: 400 mg/kg/d, 7 d) in the absence and presence 
of metformin with qPCR assay. As expected, metformin inhibited mtDNA release from activated platelets 
(Fig. 1A,B). Furthermore metformin also inhibited mtDNA release from arachidonic acid (AA)- and throm-
bin-activated platelets (Supplementary Fig. 1A). However, the mechanism behind these inhibitory effects of 
metformin is poorly recognized. As shown in Supplementary Fig. 1D, metformin has no effects on apoptosis 
in platelets. This study eliminated the possibility that the changes of extracellular mtDNA level are because of 
the changes of apoptotic bodies. Our results suggest that metformin prevented platelet membrane damage in 
activated platelets (Fig. 1C), Activated platelets treated with metformin also showed lowered lipid peroxidation 
levels as measured by Lipid Peroxidation Sensor, BODIPY® 581/591 C11 (Fig. 1D). It has been reported that cell 
membranes are highly susceptible to injury by an over-load of ROS, which then cause enhanced lipid peroxida-
tion leading to damage of the bio-membrane system19,20. In our study, we observed an elevated level of ROS in 
ADP-activated platelets as detected by CM-H2DCFDA fluorescence (Fig. 1E), but a lower level of ROS production 
when metformin was added (Fig. 1E). We found that metformin also reduced level of platelet mitochondrial 
ROS production (Supplementary Fig. 1F). Furthermore, we identified a hydrogen peroxide-induced increase in 
free mtDNA from activated platelets (Fig. 1F), while N-acetylcysteine (NAC), an ROS inhibitor, also inhibited 
mtDNA release (Fig. 1G). We further determined the hyperpolarization level of the mitochondrial membrane 
potential (Fig. 1H), intracellular ATP level (Fig. 1I) and mitochondrial routine respiration (Fig. 1J), and found 
Figure 1. Metformin suppresses the release of platelet mtDNA via inhibition of complex I. (A,B) Metformin 
influences mtDNA escape from activated platelets in vitro (metformin: 1 mM, 6 h) and in vivo (metformin: 
400 mg/kg/d, 7 d). (C) Transmission electronic microscopy imaging of platelets and mitochondria (black 
arrows) treated with metformin or without. (D) C11-BODIPY 581/591 (lipid peroxidation sensor), (E) 
ROS(CM-H2DCFDA fluorescence), (I) ATP, (H) hyperpolarization (JC-1 fluorescence ratio, FL2/FL1) Δ Ψ ,  
(J) mitochondrial routine respiration, (K) complex I values in activated platelets treated with metformin 
(metformin: 1 mM, 6 h). (F) ROS (hydrogen peroxide, 6 h) induces mtDNA escape from platelets. (G) NAC 
reduce mtDNA release from platelets (NAC: 10 mM, 6 h). (L) Low concentrations of rotenone reduce mtDNA 
release from platelets (rotenone: 12.5 nM, 6 h). Data are expressed as mean ± SD. n = 8. *P < 0.05 vs control, 
#P < 0.05 vs ADP.
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that these three key indexes for evaluating mitochondrial function were improved from mitochondrial dysfunc-
tion with metformin (1 mM, 6 h) treatment in activated platelets. The mitochondrial electron transport chain 
(ETC) is an important target that regulates mitochondrial function, including mitochondrial membrane poten-
tial, ROS, and ATP levels19. Our study found that metformin inhibited complex I activity of the platelet mito-
chondrial respiratory chain (Fig. 1K). In addition, other complexes of the mitochondrial respiratory chain were 
also evaluated. However, we did not observe any statistical differences in complex activity between metformin 
treatment and non-treatment. The low concentrations of rotenone, a known mitochondrial complex I inhibitor, 
had similar effects in this assay (Fig. 1K,L) and, as expected, also inhibited mitochondrial release (Fig. 1L). The 
effect of rotenone on platelet mtDNA release should be looking at the impact of rotenone dose response, high 
concentrations of rotenone cause platelet mitochondrial dysfunction, apoptosis and mtDNA release. As shown 
in Supplementary Fig. 1B, high concentrations of metformin also increase platelet mtDNA release. Thus, our 
results indicated that metformin lowered mtDNA release from activated platelets and suppressed mitochondrial 
dysfunction via inhibition of complex I in the ETC.
mtDNA-induced platelet activation may through DC-SIGN-dependent pathway. Overall, our 
above studies showed that metformin protected against mitochondrial dysfunction by inhibiting complex I, 
hyperpolarization, ROS production, and ROS-induced membrane damage, and subsequently prevented mtDNA 
release from activated platelets. However, because it is unclear whether mtDNA induces platelet activation, we also 
performed additional related experiments. We found that mtDNA caused increased levels of platelet aggregation 
(Fig. 2A,C) and α IIbβ 3 expression (Fig. 2B,D) in vivo (mtDNA: 50 μ g/kg/d, 7 d) and in vitro (mtDNA: 40 ng/μ L, 
6 h, 37 °C), while the addition of metformin reduced these levels (Fig. 2A–D). To further confirm the importance 
of mtDNA in metformin inhibited platelet activation it would been useful to demonstrate that elimination of 
DNA using a DNase eliminated the signal. As expected, DNase prevents inhibition of metformin on platelet 
activation (Fig. 2E,F). Furthermore, we found that the level of a certain protein, with a comparable weight to that 
of DC-SIGN, increased when we incubated platelets with mtDNA (Fig. 2G). By using a co-immunoprecipitation 
Figure 2. mtDNA induced platelet activation may through DC–SIGN dependent pathway. (A,C) mtDNA 
affects aggregation of platelets with or without metformin treatment in vivo (mtDNA: 50 μ g/kg/d, 7 d) and  
in vitro (mtDNA: 40 ng/μ L, 6 h). (B,D) mtDNA influences α IIbβ 3 level with or without metformin treatment 
in vivo and in vitro. (E,F) DNase decreases inhibition of metformin on platelet aggregation and α IIbβ 3 level 
induced by ADP in vitro (Pre-incubated for 0.5 h at 20 μ g/mL DNase I). (G) mtDNA increases DC-SIGN 
expression in vitro. (H,I) Anti-DC-SIGN (Pre-incubated for 0.5 h at 25 μ g/mL) agent decreases platelet 
aggregation and α IIbβ 3 level induced by mtDNA in vitro. Data are expressed as mean ± SD. n = 8. *P < 0.05 vs 
control, #P < 0.05 vs mtDNA.
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assay with anti-DC-SIGN antibodies, we confirmed that this protein was DC-SIGN21. Platelets express this surface 
molecule, which acts as a critical receptor in further platelet activation21–23, but had not been linked previously 
to mtDNA-induced platelet activation. Less DC-SIGN was expressed in the presence of metformin (Fig. 2G). 
Anti-DC-SIGN antibody (neutralizing antibodies against DC-SIGN, 25 μ g/mL, 0.5 h) decreased mtDNA-induced 
platelet aggregation and α IIbβ 3 expression (Fig. 2H,I). Taken together, our study has been the first to reveal that 
mtDNA released from activated platelets can act as a cellular damage factor and subsequently induce platelet 
activation may in a DC-SIGN-dependent manner. Next, we considered to confirm that mtDNA induces platelet 
activation through DC-SIGN with knockout approaches.
Metformin inhibits platelet activation in vivo and in vitro. To further assess the effect of metformin 
on platelet activation, we assessed the drug’s effect on aggregation of platelets induced by ADP, AA, and thrombin 
in vitro (Fig. 3A, metformin: 1 mM, 6 h, 37 °C) and in vivo (Fig. 3B, metformin: 400 mg/kg/d, 7 d). The results 
showed that metformin significantly suppressed platelet aggregation in all assays (Fig. 3A,B). We also found that 
three key indicators of platelet activation, α IIbβ 3 expression (Fig. 3E,F), P-selectin (Fig. 3G,H), and cytosolic 
calcium (Fig. 3I,J), were decreased in vitro and in vivo in ADP-activated platelets in the presence of metformin. 
The effects were comparable with those of aspirin used as a positive control (Fig. 3D–J). The α IIbβ 3 expression 
that key indicator of platelet activation also were decreased in AA, and thrombin-activated platelets in the presence 
of metformin (Supplementary Fig. 2A). Furthermore, because thrombosis is known to be mediated by adhesion, 
activation, and aggregation of platelets24, we evaluated the effects of metformin on platelet adhesion and activation 
on collagen-coated surfaces. The data showed that metformin effectively inhibited these processes (Fig. 3C,D).
Figure 3. Metformin inhibits platelet activation in vivo and in vitro. (A,B) Influence of metformin on 
aggregation of platelets induced by ADP, AA, and thrombin in vitro (metformin: 1 mM, 6 h) and in vivo 
(metformin: 400 mg/kg/d, 7 d). (C,D) Effect of metformin on platelet adhesion to collagen-coated surfaces 
(phalloidin-labelled platelets). (E,F) α IIbβ 3 expression in ADP-activated platelets with metformin in vitro and 
in vivo. (G,H) P-selectin expression in ADP-activated platelets with treatment in vitro and in vivo. (I,J) Influence 
of metformin on the elevation of cytosolic calcium levels in ADP-stimulated platelets in vitro and in vivo. Data 
are expressed as mean ± SD. n = 9–10. *P < 0.05 vs control, #P < 0.05 vs ADP.
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Metformin inhibits the formation of arterial and venous thrombosis in animals. In addition, we 
evaluated the effect of metformin on thrombus (metformin: 200 mg/kg twice a day for 7 days)25,26, particularly on 
diabetic rat thrombus, since metformin is an antidiabetic drug6. Metformin showed similar effects on preventing 
arterial (Fig. 4A,B,E) and venous (Fig. 4C,D,F, Supplementary Fig. 3A,B) thrombosis in normal and diabetic 
rat models. The metformin treatment significantly decreased the incidence of pulmonary embolism (Fig. 4G), 
reduced the weight and length of arterial and venous thrombus (Fig. 4A–F), prolonged the average time to occlu-
sive thrombosis in FeCl3-induced inferior vena cava and carotid arteries injury (Supplementary Fig. 3C,D), and 
improved blood viscosity (Supplementary Table 1). These results suggest that metformin may have great potential 
as an anti-thrombotic agent and are consistent with published reports stating that metformin decreases cardio-
vascular events and mortality in diabetic patients27–29. Our studies also demonstrate that metformin reduces the 
amount of plasma mtDNA and platelet DC-SIGN expression in FeCl3-induced carotid arterial thrombosis and 
partial inferior vena cava ligation induced venous thrombosis model (Supplementary Fig. 3E–H). From analysis 
of a thromboelastogram (TEG)30, we found that metformin treatment significantly improved indexes for viscoe-
lastic properties of the developing clot, thrombogenesis, and platelet activation (Fig. 4H). However, metformin 
treatment appeared not to have a significant influence on prothrombin time (PT), activated partial thrombin 
time (APTT), fibrinogen (FIB), thrombin time (TT), coagulation factors II, V, VII–XII, clot weight, and plate-
let counts (Supplementary Fig. 2B–D, Supplementary Table 2). Furthermore, the metformin treatment did not 
Figure 4. Metformin inhibits formation of FeCl3-induced carotid arterial thrombosis and partial inferior 
vena cava ligation induced venous thrombosis in animals. Decreases weight (A,E) and length (B,E) of arterial 
thrombus in diabetic and normal rats (pre-treated with 400 mg/kg/d metformin for 7 d). Decreases weight 
(C,F) and length (D,F) of venous thrombus in normal and diabetic rats. (G) Reduces mortality from pulmonary 
thromboembolism in diabetic and normal mice (metformin: 400 mg/kg/d, 7 d). (H) Thromboelastogram of 
whole blood from rats treated with or without metformin. (I) Does not significantly prolong bleeding times 
in normal and diabetic C57/BL6 mice (metformin: 400 mg/kg/d, 7 d). (J) Reduces bleeding risk (increased 
bleeding time %/inhibited thrombosis %) in diabetic and normal rats compared with the use of aspirin. (K) 
Metformin decreases the incidence of gastric ulcer in normal rats compared with the use of aspirin (metformin: 
400 mg/kg/d, 60 d. Aspirin: 30 mg/kg/d, 60 d). Data are expressed as mean ± SD. n = 9–10. *P < 0.05 vs control, 
#P < 0.05 vs aspirin.
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significantly prolong bleeding time in either normal or diabetic rats (Fig. 4I). These findings are notable, because 
a known major limitation of current antithrombotic therapies is their inability to separate thrombotic events 
from bleeding occurrences31. And the mice treated with metformin did not show any spontaneous bleeding and 
had far less bleeding risk than those treated with aspirin (Fig. 4J), the most commonly used oral antithrombotic 
drug. Our results in mice are consistent with the fact that bleeding side effects do not generally occur with clinical 
metformin treatment12. Our results also showed that, compared with aspirin32, metformin treatment (metformin: 
200 mg/kg twice a day for 60 days) led to decreased incidence of gastric ulcer (Fig. 4K). In our studies, gastric 
ulcers developed in two mice (2/10) in the aspirin-treated group (aspirin: 15 mg/kg twice a day for 60 days), 
but none appeared in mice (0/10) in the metformin-treated group. These data suggest that metformin can pre-
vent both venous and arterial thrombosis by inhibiting platelet activation, notably without a significant risk of 
bleeding.
Discussion
Metformin, an insulin-sensitizer, may improve vascular function and several physiologic abnormalities related to 
insulin resistance with fewer reported side-effects in patients with type 2 DM10. Literature reports have connected 
metformin with reduced mortality and diabetes-associated cardiovascular and cerebrovascular events in diabetic 
patients8–11. However, it is not known whether metformin is effective against thrombosis in both diabetic and 
normal individuals, and further investigation is merited to determine its precise mechanism of action with respect 
to thrombosis prevention. One advantage of normal animal thrombotic models, as opposed to diabetes-associated 
studies, is that the contribution of metformin can be assessed independently of other cardiovascular risk factors, 
such as hypercholesterolemia, hyperglycemia, obesity, and hypertension33. By using models of carotid artery and 
inferior vena cava thrombosis, we found that thrombus formation was strongly impaired in metformin-treated 
diabetic and normal rats. We also demonstrated that metformin-treated mice were more resistant to pulmonary 
thromboembolism than control mice. Normal activity of blood coagulation requires platelets as a critical factor. 
Studies have shown that platelets are involved in many biological clotting processes, including detection of vas-
cular lesions, coagulation cascade startup, and activation of other platelets15. Additional studies presented here 
provided evidence that, in the presence of metformin, platelet prothrombinase activity was markedly impaired. 
This finding is consistent with the observed decrease in α IIbβ 3 expression, P-selectin, and cytosolic calcium of 
platelets preincubated with metformin. Our results also indicated that the platelet adhesive function was reduced 
after administration of metformin. However, metformin treatment appeared to have no significant influence on 
coagulation factors and clot weight.
Antiplatelet therapy has been effective in reducing the mortality and morbidity of cardiovascular disease, the 
most common cause of death in developed countries. However, current antiplatelet agents approved by the US 
Food and Drug Administration have serious side effects, including bleeding episodes, gastrointestinal toxicity, 
neutropenia and thrombocytopenia. As stated previously, a recognized limitation of current antiplatelet thera-
pies is their inability to separate thrombotic events from bleeding occurrences31,33,34. The impact of metformin 
on hemostatic function is best exemplified by our tail bleeding time studies and chronic-type gastric ulcer eval-
uation. Intriguingly, metformin-treated mice did not show any spontaneous bleeding, abnormal tail bleeding 
times, or gastrointestinal toxicity (without gastric ulcer occurrences). Our mouse studies also demonstrated that 
metformin does not have deleterious effects on platelet properties and, therefore, suggested that long-term med-
ication would not lead to the negative effects of induced platelet death or altered platelet counts. In this study, we 
have demonstrated that metformin uniquely prevents both venous and arterial thrombosis with no significant 
prolonged bleeding time by inhibiting platelet activation. Our work presented herein suggests that further investi-
gation on metformin could lead to a novel antiplatelet therapy with fewer side-effects. Increased understanding of 
metformin’s antithrombotic activity should lead to the development of new antiplatelet drugs that are potentially 
more effective with minimal side effects. Such new therapies targeting the underlying mechanism for platelet 
dysfunction are urgently warranted.
Some indications as to the role mitochondria play in platelet function have been elucidated15–17. Early reports 
primarily examined the role that mitochondria play in meeting the energy demands required for platelet aggre-
gation and granule release16. For example, Barile et al. pointed out that inhibition of mitochondrial respiration 
in platelets could suppress platelet-stimulated blood coagulation15. Interestingly, previous work by Boudreau 
and colleagues demonstrated that activated platelets can release mitochondria18. Previously, various studies 
indicated that metformin has variable effects on hepatic mitochondrial function by inhibiting complex I in the 
mitochondrial respiratory chain13,14. While it was not determined whether metformin can protect against acti-
vated platelet-induced mitochondrial dysfunction or prevent mitochondria release from activated platelets, we 
hypothesized that metformin can inhibit platelet activation and platelet-activated blood coagulation in this man-
ner. Consistent with our hypothesis, decreased extracellular mtDNA was detected with quantitative real-time 
PCR in metformin-treated platelets. As shown in Supplementary Fig. 1D, metformin had no significant effect 
on apoptosis of platelets. Therefore it was conclude that the lowered level of extracellular mtDNA may not be 
caused by the variation of platelets apoptotic bodies. Our observations also indicated that metformin inhibited 
mtDNA release by preventing membrane damage, and mitochondrial dysfunction in activated platelets. However, 
the mechanism behind these inhibitory effects of metformin is poorly recognized and deserves further investi-
gation. Membranes are redox-sensitive, and an increased generation of ROS is one mechanism for membrane 
damage19. Our results showed that lower levels of ROS were produced when platelets were preincubated with 
metformin. We subsequently explored several possible mechanisms for metformin-induced decreased accumula-
tion of ROS in activated platelets. We first considered decreased NADPH oxidase in platelets as a potential mech-
anism, because decreased NADPH oxidase has been associated with platelet activation33. However, we did not 
observe any differences in platelet NADPH oxidase levels between metformin treatment and untreated control 
(Supplementary Fig. 1G). Glutathione peroxidase-1 (Gpx1) was also evaluated, as decreased erythrocyte Gpx1 
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activity is associated with increased cardiovascular risk in patients with coronary artery disease; however, no 
change was seen (Supplementary Fig. 1H). We next considered the potential role of superoxide dismutase as an 
enzymatic source of elevated ROS in platelets. Because ROS can be generated from superoxide by superoxide dis-
mutase33, metformin-associated decreased generation of ROS in platelets could result from decreased conversion 
of superoxide to H2O2 by superoxide dismutase. However, we consider this possibility to be unlikely, because we 
also did not detect any significant change of superoxide dismutase (Sod1) in platelets from metformin treatment 
(Supplementary Fig. 1I).
ETC is an important target that regulates ROS levels and mitochondrial function, including mitochondrial 
membrane potential, respiration and ATP levels19. As expected, our findings that complex I in the ETC was inhib-
ited in metformin-treated platelet were consistent with the observations of Piel et al. in human platelets35. In this 
study, we also found that intracellular ATP level, mitochondrial routine respiration, and hyperpolarization level of 
the mitochondrial membrane potential, three key indexes for evaluating mitochondrial function, were improved 
with metformin treatment in ADP-stimulated platelets. These findings suggest that the decrease in platelet ROS 
is caused by decreased activity of mitochondrial complex I. In agreement with this hypothesis, we found that 
preincubation of platelets with low concentrations of rotenone, a mitochondrial complex I inhibitor, resulted in 
a significant decrease in ADP-induced activation of α IIbβ 3 (data not shown). We also observed that low con-
centrations of rotenone decreased mtDNA release from ADP-induced activated platelets. Meanwhile, high con-
centrations of rotenone caused platelet mitochondrial dysfunction, apoptosis, and mtDNA release. Similarly to 
rotenone, the effect of metformin on platelet mtDNA release should be looking at the impact of metformin dose 
response, high concentrations of metformin increased mtDNA release by increasing platelet apoptosis, low con-
centrations of metformin inhibited mtDNA release by protecting mitochondrial function. Taken together, our 
results indicated that metformin lowers mtDNA release from activated platelets and suppresses mitochondrial 
dysfunction via inhibition of complex I in the ETC.
Increasing evidence demonstrates that mtDNA plays key roles in immune and inflammatory responses and 
their related diseases27,36–39, and our results indicated that metformin inhibits mtDNA release as well as platelet 
activation. However, because it is unclear whether mtDNA induces platelet activation, additional related exper-
iments were performed. We examined the effect of mtDNA on platelet pro-coagulant activity, and found that 
mtDNA-treated platelets can support efficient platelet activation in vitro and in vivo. However, the nature of the 
downstream pathways for mtDNA-mediated platelet formation remains largely unknown. DC-SIGN, a type II 
membrane protein and C-type lectin receptor that binds high-mannose-containing glycoproteins, was originally 
cloned from a placental library via its ability to bind the glycan-rich HIV-1 envelope without the assistance of 
the classic CD4 virus receptor22. Although previous studies have shown that DC-SIGN interacts with platelet 
activation21, they were not then linked to mtDNA-induced platelet activation. When we incubated platelets with 
mtDNA, the level of a certain protein was increased. Next, we confirmed that this protein was DC-SIGN by 
using a co-immunoprecipitation assay with anti-DC-SIGN antibodies. In addition, we found that anti-DC-SIGN 
(neutralizing antibodies against DC-SIGN) inhibition abolished the potentiating effects of mtDNA on platelet 
activation, further confirming the critical role of DC-SIGN in mtDNA-mediated platelet activation. We next 
studied the role of metformin in mtDNA-mediated platelet activation. We found that platelet activation was 
dramatically decreased following metformin preincubation. Taken together, our study is the first to reveal that 
the mtDNA released from activated platelets can act as a cellular damage factor and subsequently induce platelet 
activation may via a DC-SIGN-dependent pathway. We next considered to confirm and assure mtDNA induces 
platelet activation through DC-SIGN with gene knockout approaches. Our work presented here is consistent 
with other recent findings and suggests possible mechanism(s) for metformin’s role in reduced mortality and 
diabetes-associated thrombotic complications, related to inhibition of platelet activation, prevention of mito-
chondrial dysfunction, and reduction in the release of free mtDNA.
As of 2014, DM was diagnosed in more than 20 million adults in the United States and likely remained undi-
agnosed in millions more. Thrombotic cardiovascular events, in which platelets have essential functions, will be 
a likely cause of death in an estimated 65% of diabetic patients. Although aspirin is most commonly used to pre-
vent and treat heart attacks and strokes in clinical practice, previous work has shown that 10% to 40% of diabetic 
patients are biochemically resistant to this drug. Due to this important concern, a better understanding of and 
new therapies to target the underlying mechanism for platelet dysfunction must be found1–4. Our findings suggest 
that metformin could be a promising lead as a new class of antiplatelet agents that are highly effective at inhibiting 
platelet activation in vitro and in vivo.
In conclusion, the research presented here has established a novel therapeutic strategy for platelet abnor-
malities in DM and a general strategy to prevent cardiovascular complications. Future studies will be required 
to develop new antiplatelet drugs that are potentially more effective without bleeding risk and as possible treat-
ments for metabolic syndrome. Furthermore, our team will evaluate whether or not metformin also inhibits 
anionic phospholipid exposure, microvesicle release, and other damage-associated molecular pattern molecules 
(DAMPs) such as high-mobility group box 1 (HMGB1) in the future. We will use other pharmacological and 
knockout approaches to confirm and assure mtDNA induces platelet activation through DC-SIGN, and research 
DC-SIGN downstream signaling events, and consider other receptors that might be implicated in mtDNA 
dependent platelet activation e.g. TLR9. On the basis of our studies, we now propose that drugs targeting platelet 
mtDNA may be effective against platelet dysfunction and thrombosis. These mechanistic studies provide new 
insights into platelet abnormalities to inhibit thrombosis. Beyond the well-recognized pivotal role in thrombosis 
and hemostasis, platelets also play a critical role in inflammatory and infectious diseases, and increasing evi-
dence indicates that bacterial infection predisposes for atherosclerosis and thrombotic events26. Several previous 
studies provided support that mtDNA is also involved in immune and inflammatory responses and their related 
diseases36–39. In this study, we reported that mtDNA is released from activated platelets and acts as an ‘agonist’ to 
induce platelet activation and thrombosis. To our knowledge, this study is the first to report that mtDNA may play 
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a connecting role in thrombosis and inflammation/immunity during bacterial infection and, thus, is an important 
link to study in elucidating the underlying mechanisms that thrombotic events play in inflammation, infection, 
cancer, DM, etc.
Materials and Methods
Animal models and diets. Male Type 2 diabetic rats (type 2 DM), Sprague-Dawlecy (SD) rats and C57/BL6 
mice were obtained from the West China Hospital Experiment Animal Center (Chengdu, China). The rats were 
maintained in an animal house with a constant temperature of 25 °C and a 12/12-hour of light/dark cycle. Food 
and water were provided ad libitum. All animals were treated according to the experimental protocols approved 
by the Bioethics Committee of West China Center of Medical Sciences. Diabetic rats were induced by combina-
tion of high-fat diet-fed and low-dose streptozotocin (STZ, 45 mg/kg, ip) injection (Final fasting blood glucose 
level: Control 4.8 ± 0.8 mmol/L; Diabetic 16.4 ± 2.2 mmol/L)40. All animal studies included 9–10 rats or mice per 
group, aged 9–12 weeks at the time of study. Animals were randomly allocated to control groups, model groups, 
and treatment groups. Metformin was administrated orally to animals at 200 mg/kg twice daily for seven days. 
Aspirin was administrated at 15 mg/kg in the same manner. Ferric chloride induced carotid arterial injury and 
venous thrombosis experiments were conducted according to the previously described methods with a minor 
modification25. Briefly, a piece of filter paper (2 mm × 10 mm ) pre-saturated with 3 μ L of 1 mM FeCl3 solution 
(arterial) or 10 mm × 10 mm paper pre-saturated with 20 μ L of 2 mM FeCl3 solution (venous) was placed on the 
arterial or venous cava. Blood flow was monitored continuously for 90 minutes or until stable occlusion occurred, 
at which time the experiment was terminated. Stable occlusion was defined as the time at which blood flow 
remained absent for ≥ 10 minutes. Finally, weight and length were measured. Inferior vena cava ligation exper-
iments were performed as described under aseptic conditions41. Briefly, rats were anesthetized with 5% chloral 
hydrate (0.7 mL/100 g) and placed in a supine position. A midline laparotomy was performed, and then intestines 
were exteriorized and sterile saline was applied to prevent drying during the whole procedure. The inferior vena 
cava (IVC) was ligated by a 7.0 polypropylene suture below the renal veins for obtain complete blood stasis. After 
surgery, peritoneum and skin were closed and the animal was allowed to recover. After 48 hours, the IVC was 
harvested and weighed for analysis. Pulmonary thromboembolism was induced by a method as described42. The 
number of dead or paralyzed mice was recorded and the percentage of protection was calculated. The bleeding 
time was measured by a previously described method25,42.
Chronic-type gastric ulcer. Male, C57/BL6 mice (20 ± 3 g) were administrated orally metformin 200 mg/kg 
twice a day for 60 days. Aspirin was administrated 15 mg/kg in the same way, and mice were sacrificed on the 
61st day. The stomach was examined by an observer unaware of the treatments and any macroscopically visible 
ulcers were measured with calipers. An ulcer area (in mm2) was calculated for each stomach. Samples of macro-
scopically normal and damaged tissue were excised, fixed in neutral buffered formalin, and processed by routine 
techniques for subsequent histological evaluation. The small intestine was examined for signs of injury32.
Platelet preparation. Washed platelets were prepared by differential centrifugation as described previ-
ously33,41,43. Briefly, venous blood samples were collected in citrate by standard venous puncture from rats, and the 
first 2 mL of blood was discarded to avoid artificial activation. Whole blood was centrifuged (160 g for 10 min) in 
the presence of PGI2 (1 mM) to obtain platelet-rich plasma (PRP). Platelets were subsequently pelleted by centrif-
ugation (1000 g for 5 min). The platelet pellet was then suspended in a washing buffer containing Tyrode’s buffer, 
10% of acid-citrate-dextrose solution, 2 mM EDTA and 1 mM PGI2 and was centrifuged again. Final samples 
were resuspended in modified Tyrode buffer. Platelet purity was confirmed by flow cytometric measurement of 
CD41a expression.
Platelet adhesion under flow conditions assay. Platelets were incubated at 37 °C for 6 h in the absence 
or presence of metformin (1 mM), and stained with phalloidin (200 nM) (Sigma-Aldrich) for 30 min at 37 °C as 
described. A collagen-coated coverslip (Neuvitro) was mounted on a custom-made flow chamber (Chamlide 
CF; Live Cell Instruments). The fluorescently labeled platelets were then perfused over a matrix of collagen at 
150 s−1 using a syringe pump (Harvard Apparatus). Non-adherent platelets in the chamber were washed with 
PBS. Adherent platelets were fixed with cold 4% paraformaldehyde for 15 min and then washed with PBS. The 
perfusion was live-monitored with a fluorescence microscope (Nikon TE-2000S; Nikon, Melville, NY, USA) 
equipped with a Nikon DS-2MBWc-U1 CCD camera (Nikon)34,43,44.
P-selectin and integrin αIIbβ3 assay. After treatment (in vitro: metformin: 1 mM, 6 h, 37 °C; aspirin: 
0.1 mM, 6 h, 37 °C; mtDNA: 40 ng/μ L, 6 h, 37 °C. In vivo: metformin: 200 mg/kg twice a day for 7 days; aspi-
rin: 15 mg/kg twice a day for 7 days; mtDNA: 25 μ g/kg twice a day for 7 days), platelets were incubated with 
PE-CD62P (Sigma, USA) or PAC-1-FITC (Sigma, USA) for 30 min in the dark, and reaction was stopped by 
adding ice-cold PBS. The P-selectin and integrin-α IIbβ 3 expression on the platelets was measured at 585 nm 
(FL2) and 530 nm (FL1) by using flow cytometer (Becton - Dickinson, San Jose, CA, USA). In selected experi-
ments platelets were pre-incubated for 0.5 h at 37 °C with neutralizing antibodies against DC-SIGN (120507; R&D 
Systems, USA, 25 μ g/mL) or DNase I (Genentech, USA, 20 μ g/mL)33,45.
Lipid peroxidation, ROS, Ca2+ and ATP assay. Platelets were incubated with metformin (1 mM) for 6 h 
at 37 °C. Subsequently, platelets were loaded with CM-H2DCFDA (General Oxidative Stress Indicator, Thermo 
Fisher Scientific, USA) or MitoSOX™ Red Mitochondrial Superoxide Indicator (Thermo Fisher Scientific, USA) 
at room temperature in the dark and measured by a fluorescence microplate reader (Aynergy Mx, BioTek, USA). 
Lipid peroxidation of platelets was assayed using a commercial kit (BODIPY® 581/591 C11, Thermo Fisher 
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Scientific, USA). The levels of cytosolic calcium were analyzed by flow cytometer using Fluo-3-AM (Sigma, USA) 
as a probe, and ATP levels were determined using a commercial kit (Sigma, USA)15,35,46,47.
Complex I assay. Platelets were incubated with metformin (1 mM) for 6 h at 37 °C. Complex I 
(NADH-ubiquinone 1 reductase) levels were assessed with MitoCheck® Complex I Activity Assay Kit (Item No 
700930, Cayman Chemical, USA) (Abcam, USA)35,46.
Mitochondrial membrane potential assay. Treated platelets implanted in a 48-well plate were incu-
bated with JC-1 solution (10 μ g/mL) at 37 °C for 15 min. Then, the platelets were harvested and resuspended in 
0.2 mL of Tyrode’s buffer. The Δ ψ of labeled platelets was measured by a confocal microscope (Nikon ECLIPSE 
Ti, Japan)35,46.
Mitochondrial routine respiration assay. The effect of metformin on mitochondrial respiration in 
platelets was assay as described previously35. Briefly, after stabilization of routine respiration in MiR05 medium, 
1 mM metformin, 12.5 nM rotenone, or either vehicle was added. Oligomycin (1 μ g/mL), ATP-synthase inhibitor 
was added to assess LEAK respiration. The maximal capacity of electron respiratory chain using endogenous 
substrates (ETS) was measured by application of FCCP. Respiration was sequentially blocked by rotenone (the 
complex I inhibitor, 2 μ M), antimycin (the complex III inhibitor, 1 μ g/mL) and sodium azide (the complex IV 
inhibitor, 10 mM) to assess residual oxygen consumption.
Transmission electronic microscopy imaging of platelets and mitochondria assay. Washed 
platelets were prepared treated with and without metformin (1 mM, 6 h) and activated or not by ADP, then were 
fixed with 2.5% glutaraldehyde for at least 24 h and processed for standard dehydration. Briefly, samples were first 
washed (3 × 10 min) with Tyrode’s buffer then fixed with osmium tetroxide (1% in sodium cacodylate buffer) for 
90 min. Samples were washed again (3 × 10 min) with Tyrode’s buffer and subsequently processed for alcohol 
dehydration steps (50, 70, 95 and 100% EtOH, 10 min each steps). Samples were then dipped in 100% EtOH for 
40 and 10 min respectively, and air-dried overnight. Samples were then coated with palladium and observed with 
a JEOL 6360LV transmission electron microscope (Tokyo, Japan)18,27,48.
In vitro blood clot dissolution assay. Dissolution of blood clot assay in vitro was measured as described 
with slight modification. In brief, venous blood of rats was gathered into a dry Petri dish and clotted at room tem-
perature. The blood clot was cut into 100 ± 20 mg weight slices after 24 h. Subsequently, these clot slices were put 
into a 12-well plate (one slice per well) and incubated with or without metformin (metformin: 1 mM, 6 h, 37 °C). 
The dissolution rate of blood clot was calculated and expressed as: Dissolution rate (%) = [(W1–W2)/W1]*100; 
where W1 represents clot weigh, and W2 indicates the residual clot weight49.
Hematological parameters. The whole blood was collected by cardiac puncture and treated by different 
anticoagulants: 3.8% trisodium citrate (9:1, v/v), 10% EDTA (9:1, v/v), and heparin. Platelet-rich plasma (PRP) 
was obtained by centrifugation at 100 g for 10 min. Platelet-poor plasma (PPP) was prepared by centrifugation at 
1000 g for 10 min. Thrombelastogram was measured by thrombelastography (Haemoscope, USA). Blood coagu-
lation factor was measured by a kaolin-activated one-stage partial thromboplastin time method using mice Factor 
plasma (George King Biomedical). An automated hematology analyzer was used to evaluate the viscosity of 
those samples. Platelet counts (PLT), mean platelet volume (MPV), immature platelet fraction (IPF), plateletcrit 
(PCT) and platelet distribution width (PDW) of blood samples were measured by automatic blood cell analyzer 
(SYSMEX SF-3000, Japan). The platelet aggregation assay was performed at 37 °C using a Lumi-Aggregometer 
(Chrono-log). Aggregation was initiated by the addition of ADP solution (final concentration, 20 μ M), thrombin 
(0.1 U/mL) and arachidonic acid (AA: 900 μ M) in vivo (pre-treated with 400 mg/kg/d metformin, 50 μ g/kg/d 
mtDNA or control buffer for 7 d) and in vitro (pre-incubated with 1 mM metformin, 40 ng/μ L or control buffer for 
6 h at 37 °C), and recorded for 5 min. In selected experiments platelets were pre-incubated for 0.5 h at 37 °C with 
neutralizing antibodies against DC-SIGN (120507; R&D Systems, USA, 25 μ g/mL)41,33,49–51.
mtDNA preparation. The mtDNA was isolated from platelets using a commercial kit (Mitochondria DNA 
Isolation Kit, Biovision), using western blotting confirm the absence of non-mitochondrial proteins to demon-
strate the purity of the mtDNA preparations, and using consistent approaches in this study. Quantification of 
mtDNA was determined by qPCR assay using a PRISM 7300 sequence detection system (Applied Biosystems)18.
mtDNA quantification in vitro. Platelets were isolated from the blood of rats and purity was confirmed by 
flow cytometric measurement of CD41a expression. Then platelets treated with 1 mM metformin for 6 h at 37 °C. 
After centrifugation at 700 g for 10 min to remove the pellet (platelet), extracellular mtDNA was isolated from the 
supernatant using a Mitochondrial DNA Isolation Kit (Catalog K280-50, Biovision, USA), using western blotting 
confirm the absence of non-mitochondrial proteins to demonstrate the purity of the mtDNA. The concentration 
of mtDNA was determined by a spectrophotometer (Nanodrop2000, Thermo) or qPCR assay using a PRISM 
7300 sequence detection system (Applied Biosystems)18,36,50,52.
mtDNA quantification in vivo. Seven days after treatment with 400 mg/kg/d metformin, rats were sacri-
ficed and blood was collected, and mtDNA was extracted with Mitochondrial DNA Isolation Kit (Catalog K280-50, 
Biovision, USA) for analysis, and confirm the purity of the mtDNA. mtDNA level was measured by qPCR assay 
using a PRISM 7300 sequence detection system (Applied Biosystems) as previously described18,36,50,52. The primer 
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sequences were rat NADH dehydrogenase 1 gene (mtDNA): forward CGCCTGACCAATAGCCATAA, reverse 
ATTCGACGTTAAAGCCTGAGA. All samples were measured with standards at the same time.
DC-SIGN expression assay. Platelets were resuspended in Tyrode’s buffer, then treatment with or without 
mtDNA (mtDNA: 40 ng/μ L, 6 h). Immunoprecipitation of protein assemblies was performed by incubation of 
these pools with purified and identified monoclonal antibodies against DC-SIGN (MR-1, Santa Cruz Biotech, 
USA), and then capture of the immune complexes on Protein G superparamagnetic Microbeads (Miltenyi Biotec, 
Germany) as described previously22. Immunoprecipitates were subjected to Western blot using polyclonal anti-
bodies against DC-SIGN. Immunoprecipitated with Streptavidin-agarose (Sigma Aldrich, USA), and then immu-
noprecipitated material was analyzed by SDS-PAGE, Western blot with antibodies specific for DC-SIGN.
mRNA Levels of Nox2, Gpx1, Sod1 assay. Levels of mRNA for Nox2, Gpx1, Sod1, and 18S were meas-
ured by quantitative real-time PCR as described previously33. First, isolating total RNA from washed platelets 
with Trizol reagent (Invitrogen, Carlsbad, CA). Reverse-transcribed cDNA was incubated with PCR primers, 
6-carboxy fluorescein-labeled probes (Applied Biosystems) and TaqMan Universal PCR mix at 50 °C for 2 min-
utes and then at 95 °C for 10 minutes. After that, 40 cycles of 95 °C for 15 seconds and 60 °C for 1 minute. Using 
the comparative threshold cycle (Δ Δ CT) method to quantification with values normalized of 18S and expressed 
relative to levels in platelet without metformin preincubation. Platelet purity was confirmed by flow cytometric 
measurement of CD41a expression33.
Western blot analysis. Washed platelets were incubated with metformin for 6 h. The platelet were harvested 
and lysed using lysis buffer, after that the solution was centrifuged. After protein concentrations were determined, 
individual platelets lysates were separated with sodium dodecyl sulfate polyacrylamide gel electrophoresis (10% 
gel, SDS–PAGE), subsequently, platelets were transferred onto nitrocellulose membranes. The target proteins in 
the membranes was blocked with 5% nonfat milk, and probed with anti-caspase 3 (Cell Signaling Technology, 
Danvers, USA), overnight. The membranes were incubated with peroxidase-conjugated secondary antibody for 
2 h. and then visualized with ECL Western Blotting Detection Reagents (Amersham Pharmacia Biotech)53.
Statistical analysis. The data are expressed as mean ± SD. Multiple comparisons were made by appropriate 
analysis of variance, whereas individual group samples were compared by Student’s t-test. In all cases P values 
were two tailed and P values < 0.05 were considered to indicate significance.
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